Cognition Therapeutics, Inc. (CGTX)
$2.37
+0.27
(+12.86%)▲
Performance
- $2.10$2.52$2.37
11.39%
Downside
Day's Volatility :16.67%
Upside
5.96%
- $0.90$2.95$2.37
62.02%
Downside
52 Weeks Volatility :69.49%
Upside
19.66%
Returns
| Period | Cognition Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 7.69% | 6.5% | 0.0% |
6 Months | -12.5% | 7.1% | 0.0% |
1 Year | 20.0% | 9.8% | 0.0% |
3 Years | -83.56% | 14.2% | -20.2% |
Highlights
Market Capitalization | 73.7M |
Book Value | $0.72 |
Earnings Per Share (EPS) | -0.92 |
Wall Street Target Price | 8.2 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -82.61% |
Return On Equity TTM | -89.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -55.8M |
Diluted Eps TTM | -0.92 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.97 |
EPS Estimate Next Year | -1.05 |
EPS Estimate Current Quarter | -0.25 |
EPS Estimate Next Quarter | -0.23 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 245.99%
Technicals Summary
Sell
Neutral
Buy
Cognition Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cognition Therapeutics, Inc. | 23.53% | -12.5% | 20.0% | -83.56% | -83.56% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cognition Therapeutics, Inc. | NA | NA | NA | -0.97 | -0.89 | -0.83 | NA | 0.72 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cognition Therapeutics, Inc. | Buy | $73.7M | -83.56% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Cognition Therapeutics, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 41.6%
Institutional Holdings
AIGH Capital Management, LLC
4.74%Vanguard Group Inc
2.30%Awm Investment Company Inc
1.62%Alyeska Investment Group, L.P.
1.25%Timelo Investment Management Inc.
1.20%Corsair Capital Management LLC
0.71%
Company Information
cognition therapeutics inc. is a drug discovery and development company located in pittsburgh, pennsylvania. founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.
Organization | Cognition Therapeutics, Inc. |
Employees | 25 |
CEO | Ms. Lisa Ricciardi |
Industry | Services |
